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Plasminogen activator urokinase expression reveals
TRAIL responsiveness and supports fractional
survival of cancer cells
V Pavet*,1, Y Shlyakhtina1, T He2, DG Ceschin1,4, P Kohonen2,5, M Pera¨la¨2, O Kallioniemi3 and H Gronemeyer*,1
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10/Apo2L) holds promise for cancer therapy as it induces
apoptosis in a large variety of cancer cells while exerting negligible toxicity in normal ones. However, TRAIL can also induce
proliferative and migratory signaling in cancer cells resistant to apoptosis induced by this cytokine. In that regard, the molecular
mechanisms underlying the tumor selectivity of TRAIL and those balancing apoptosis versus survival remain largely elusive. We
show here that high mRNA levels of PLAU, which encodes urokinase plasminogen activator (uPA), are characteristic of cancer
cells with functional TRAIL signaling. Notably, decreasing uPA levels sensitized cancer cells to TRAIL, leading to markedly
increased apoptosis. Mechanistic analyses revealed three molecular events taking place in uPA-depleted cells: reduced basal
ERK1/2 prosurvival signaling, decreased preligand decoy receptor 2 (DcR2)-death receptor 5 (DR5) interaction and attenuated
recruitment of DcR2 to the death-inducing signaling complex upon TRAIL challenge. These phenomena were accompanied by
increased FADD and procaspase-8 recruitment and processing, thus guiding cells toward a caspase-dependent cell death that is
largely independent of the intrinsic apoptosis pathway. Collectively, our results unveil PLAU mRNA levels as marker for the
identification of TRAIL-responsive tumor cells and highlight a key role of uPA signaling in ‘apoptosis versus survival’ decision-
making processes upon TRAIL challenge.
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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/TNFSF10/Apo2L) is a member of the TNF family that
induces apoptosis in a large variety of cancer cells while
sparing normal ones.1 This cytokine binds as homotrimer to
the extracellular domains of its plasma membrane-bound
receptors inducing their oligomerization. Four TRAIL-specific
receptors have been described, comprising two death
receptors (DRs) that are able to trigger apoptosis
(TNFRSF10A/TRAILR1/DR4, TNFRSF10B/TRAILR2/DR5)
and two decoy receptors (DcRs) that bind the ligand but do
not trigger apoptotic signaling (TNFRSF10C/TRAILR3/DcR1,
TNFRSF10D/TRAILR4/DcR2).2–5 TRAIL binding to DR4 and
DR5 induces the formation of the death-inducing signaling
complex (DISC) owing to the recruitment of the specific
adaptor protein FADD, which in turn engages initiator
procaspase-8 and/or procaspase-10. DISC formation enables
the autocatalytic cleavage and further activation of procas-
pases, thus triggering the death-executing cascade.6,7 Once
an apoptosis-proficient DISC is formed, procaspases are
activated to generate two possible scenarios: either the
caspase cascade triggered by initiator caspases is sufficient
to commit the cell to apoptosis (referred to as type I cells) or
the additional activation of the intrinsic apoptosis pathway is
required to induce cell death (type II cells).8 Notably, the final
cell fate upon TRAIL challenge depends on multiple cellular
factors including sequestration of the ligand by DcR1 and/or
DcR2 at the cell surface, which can trigger survival signal-
ing,9–11 the recruitment of the non-functional procaspase
homolog cFlip12–14 and the relative levels of proteins that
regulate the activation of the intrinsic mitochondrial pathway
and/or modulate the activity of executor caspases.15,16
Importantly, it was also demonstrated that TRAIL induces
proliferative, survival, migratory and inflammatory signals
via activation of NF-kB, PI3K/Akt, MAPK and JNK.17 The
existence of non-apoptotic TRAIL signaling was demon-
strated for apoptosis-resistant cancer cells, primary childhood
leukemia and non-tumorigenic scenarios such as rheumatoid
arthritis.17–20 Therefore, depending on their response to
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TRAIL, cancer cells can be grouped into three classes:
(i) the entire population commits to apoptosis, (ii) is inherently
resistant to cell death induced by TRAIL or (iii) only a part of the
cell population dies, while a significant fraction survives the
treatment and may even proliferate (referred to as ‘fractional
killing’).21 From the mechanistic point of view, it was shown that
activation of survival pathways by TRAIL involves assembly of a
secondary signaling complex that retains theDISC components
FADD and caspase-8, and recruits RIP1, TRAF2, TRADD and
NEMO/IKK.22 However, contrary to the well-known cellular
mechanisms mediating TRAIL-induced cell death, the under-
standing of how TRAIL and TRAIL receptors induce the
formation of this secondary complex and the triggering of
non-apoptotic cascades is still in its infancy.
Taken together, the numerous cellular factors modulating
the response to TRAIL and the dual nature of the signaling
triggered by this cytokine may lead to the generation of
resistant populations. In that regard, even though combining
TRAIL-based approaches with multiple therapeutic agents
improves the apoptotic response and diminishes the chances
to generate resistance,23 only proteasome inhibitors were
shown to revert acquired TRAIL resistance.24 Therefore, the
identification of tumor features predicting the response of
cancer cells to TRAIL, the understanding of the mechanisms
orchestrating the outcome and the characterization of
molecular targets that will improve the initial apoptotic
response are important goals to achieve.
By comparative transcriptome profiling of stepwise
tumorigenesis systems,25,26 we observed that PLAU mRNA
levels increase in tumorigenesis models and primary human
tumors relative to normal tissue and correlate with sensitivity
to TRAIL-induced cell death. We demonstrate that diminish-
ing urokinase plasminogen activator (uPA) levels leads to
decreased ERK1/2 survival signaling, thus lowering the
cellular threshold to trigger TRAIL-induced apoptosis.
Importantly, we show that uPA depletion alters the DISC
composition by reducing the preligand and TRAIL-induced
DcR2–DR5 interaction. Collectively, these molecular events
lead to the formation of an apoptosis-proficient DISC,
resulting in pronounced caspase-dependent apoptosis and
preventing the generation of resistant populations. All in all,
our work unveils an intricate cross-talk between uPA and
TRAIL signaling, which highlights the use ofPLAUmRNA as a
marker of response and as a potential target for improving the
apoptogenic action of TRAIL.
Results
Stepwise human tumorigenesis systems as cellular
model to study TRAIL-induced signaling. Although the
natural process of carcinogenesis is highly complex and
specific to each cell type and/or carcinogenic insult, in vitro
models recapitulate the basic events necessary for cellular
transformation.25,26 In these models, normal primary human
cells are transformed in a stepwise manner by the introduc-
tion of the catalytic subunit of telomerase (hTERT), the early
region of the SV40 virus (SV40 ER) and the activated allele
of H-ras (H-rasV12) (Figure 1a). These cellular systems
display several hallmarks of tumorigenesis27 and allow
comparing cancer cells with their normal progenitors, which
is difficult to achieve with cancer cell lines derived from
primary human tumors. We observed that normal cells from
epithelial and mesenchymal origins (human embryonic
kidney (HEK), foreskin fibroblasts (BJ), respectively) are
resistant to TRAIL-induced cell death, whereas sensitivity to
apoptosis is acquired along the transformation process, with
transformed cells displaying the major apoptotic rate
(Figure 1b). Therefore, in line with previous reports,28–31
our data indicate that stepwise tumorigenesis systems
recapitulate the tumor selectivity reported for TRAIL. Inter-
estingly, we observed that transformed cells from stepwise
models display fractional killing even when exposed to high
doses of TRAIL (460-fold above the IC50; Figures 1b and c
(population 1) and Supplementary Figures 1a and b).
Furthermore, cells surviving the first challenge remained
resistant to further TRAIL treatments (Figure 1c, populations
2 and 3) and continued to proliferate in the presence of the
cytokine (Figure 1d and Supplementary Figure 1c). Notably,
when TRAIL treatment was discontinued, the resistant cell
population reverted to the initial apoptotic rate (Figure 1c,
population 4). The reversible nature of resistance suggests
that it is not based on the selection of inherently resistant
clones within the initial population, and that its establishment
and maintenance is TRAIL-dependent. Taken together,
these results indicate that stepwise models are valuable cell
systems for the identification of genes whose altered
expression is characteristic of tumor cells, and whose
products may modulate apoptosis versus survival signaling
triggered by this cytokine.
PLAU mRNA levels correlate with TRAIL-induced
apoptosis in cancer cells. To identify genes over-
expressed in cancer cells relative to normal ones and whose
encoded proteins may modulate the response to TRAIL, we
compared the transcriptomes of normal, immortalized and
transformed cells from stepwise models (HEK versus HA1ER;
BJ versus BJELR; HA1E versus HA1ER; BJEL versus
BJELR). Genes with increased expression in transformed cells
relative to normal and immortalized ones were selected (fold
change 42.5; P-value o0.01). From 316 genes that showed
higher expression in HA1ER than in HEK cells, 39 also
displayed a significant upregulation from the immortalization to
transformation step (HA1ER versus HA1E; Figure 2a and
Supplementary Figure 2a). A similar analysis of the BJ model
revealed a set of 20 genes with such characteristics (Figure 2a
and Supplementary Figure 2b). A comparison of the two
systems identified four genes showing high expression levels
in transformed cells from both stepwise models (Figure 2a).
Among those, only PLAU mRNA was significantly increased in
a panel of primary human tumors from different tissue origins
as compared with normal tissue (Figure 2b; IST database, see
Materials and Methods). In line with this, in silico analysis
revealed that PLAU mRNA was significantly increased in
breast cancer as compared with normal breast tissue,
particularly in tumors showing a Her2þ , PgR and/or p53
mutant phenotype (Figure 2b and Supplementary Figure 2c).
Moreover, we observed that higher levels of PLAU mRNA
correlate with a reduced relapse-free survival in breast
cancer patients (Figure 2c), as previously reported for its
encoded protein uPA.32,33
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Importantly, previous studies have revealed a correlation
between high uPA levels and poor response of human tumors
to standard cancer therapies.34–36 To elucidate a potential link
between PLAU expression and response to TRAIL, these two
features were first correlated in a study of 11 breast and
prostate cancer cell lines. Interestingly, a direct correlation
between PLAU mRNA levels and TRAIL-induced apoptosis
was observed (Figure 2d). A similar analysis was performed
with a publically available transcriptome data set of 20 breast
cancer cell lines.37 These cell lines were classified into two
groups according to their apoptotic response toward TRAIL
(death rate higher or lower than 50%) and PLAUmRNA levels
for each group were assessed from the transcriptome data
sets (Figure 2e). As observed in our initial study (Figure 2d),
cell lines triggering prominent apoptosis presented higher
levels ofPLAUmRNA (Figure 2e). Taken together, these data
demonstrate that high PLAU mRNA levels are indicative for
cancer cells that exhibit a functional TRAIL apoptotic signaling
cascade, independently of their genetic background, tissue
origin and the transformation events that led to the
malignancy.
PLAU and PLAUR expression support cell survival upon
TRAIL challenge. A positive correlation between PLAU
expression and TRAIL-induced apoptosis does not a priori
imply that uPA supports the apoptogenic response to TRAIL.
Indeed, uPA and its membrane-bound receptor urokinase
plasminogen activator receptor (uPAR) have been primarily
documented as promoting the proliferation and survival of
cancer cells;38–40 however, other reports propose that
uPA/uPAR may support cell death.41–43 Notably, the
previously analyzed cancer cell lines and stepwise trans-
formed cells with high expression of PLAU mRNA show
fractional killing (Figures 1b, d and 2d and Supplementary
Figure 1). Therefore, we evaluated whether uPA was
functionally involved in the response to TRAIL, either by
supporting apoptosis or survival upon exposure to this
cytokine. Interestingly, increased apoptosis was observed
in BJELR cells upon depletion of uPA or its membrane-
bound receptor uPAR (Figures 3a and b and Supplementary
Figures 3a and b). Comparable results were obtained when
uPA or uPAR were depleted in HA1ER cells (Supplementary
Figures 3c–e). These data indicate that uPA and uPAR
are factors that counterbalance TRAIL-induced apoptosis
in H-rasV12 tumorigenic cells independently of their
genetic background and highlight their functional relevance
in the generation of resistant populations upon TRAIL
challenge.
Figure 1 RAS-derived stepwise tumorigenesis models recapitulate TRAIL-tumor-selective apoptosis and display fractional killing and proliferation upon treatment.
(a) Scheme representing RAS-derived stepwise tumorigenesis models generated from human foreskin fibroblast (BJ) and human embryonic kidney cells (HEK). Genetic
elements introduced for stepwise transformation are indicated. (b) Apoptosis observed in populations of normal, immortalized and RAS-transformed cells derived from HEK
and BJ stepwise tumorigenesis models. Basal cell death in untreated populations (control; white bars) and cell death after 16 h of treatment with 1mg/ml of TRAIL (TRAIL;
black bars) is displayed. Apoptosis was analyzed by flow cytometry as the percentage of APO 2.7-positive cells. Histograms represent the mean±S.D. from at least three
independent biological replicates. (c) Apoptosis was analyzed as in (b) after 16 h of treatment with 1 mg/ml TRAIL in populations of BJELR-naive cells (population 1), resistant
cells obtained from 24 (population 2) or 48 (population 3) hours of pre-exposure to TRAIL (500 ng/ml) and revertant cells (population 4) obtained from a pretreatment of BJELR
cells with TRAIL (500 ng/ml) during 48 h, followed by a release from exposure to the cytokine during 12 days before receiving a new dose of 1 mg/ml TRAIL during 16 h.
Histograms represent the mean±S.D. from two independent biological replicates, representative of at least three independent experiments. Statistical significance in (b and c)
was calculated by applying two-tailed, unpaired Student’s t-test, ***P-valueo0.0005, *P-valueo0.05. (d) Proliferation of BJELR cells upon sequential treatment with TRAIL.
Cells were plated and allowed to proliferate during 20 h before receiving a first dose of TRAIL (100 or 400 ng/ml, as indicated), were maintained under continuous exposure to
the cytokine and further received sequential treatments at the indicated time points (arrows). Untreated cells were grown in parallel as proliferation controls. Images were
acquired every hour using INCUCYTE and confluency was evaluated as the percentage of the surface covered by cells. The mean value obtained from two independent wells
per time point is displayed and is representative of four independent biological replicates
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uPA depletion lowers the cellular threshold for triggering
caspase-dependent TRAIL-induced apoptosis. It is
generally believed that low doses of TRAIL induce a poor
apoptotic response and may generate resistance, whereas
exposure to high levels of this cytokine results in extensive
cell death, indicating the existence of a cellular threshold
for triggering apoptosis (referred hereafter as ‘sensitivity’).
To evaluate whether uPA knockdown modifies sensitivity to
TRAIL-induced cell death, uPA-depleted cells were exposed
either to high doses of TRAIL during different time points
Figure 2 PLAU mRNA level increases during neoplastic transformation and is a tumor feature whose expression correlates with the rate of apoptosis triggered in response
to TRAIL. (a) Expression heatmaps corresponding to the four upregulated genes common between HEK and BJ RAS-derived stepwise models. IL1B: interleukin 1b; PLAU:
plasminogen activator urokinase;G0S2: G0/G1 switch 2 and ALDH1A3: aldehyde dehydrogenase 1 family, member A3. Results from four independent transcriptome datasets
(‘array 1–4’) are displayed. Mean fold change (‘f.c.’) differences in their expression between normal and transformed cells from each model are indicated. (b) G0S2, IL1B,
ALDH1A3, and PLAU mRNA levels were analyzed for 1840 healthy and 6806 malignant human primary samples from different tissue origin using the GeneSapiens database
(http: //www.genesapiens.org). Box plots displaying median and interquartile range (25–75%) of mRNA levels in each data set are shown. For PLAU mRNA, expression in
normal and malignant breast cancer samples is depicted. Statistical significance of the difference between groups was calculated with two-tailed unpaired Student’s t-test.
*P-valueo0.05. (c) Relapse-free survival curve of breast cancer patients according to PLAU mRNA levels. Three hundred and sixty-eight patients were ranked according to
the expression level of PLAU mRNA and divided into 184 PLAU mRNA high and 184 PLAU mRNA low patients. The percentage of patients with relapse-free survival is plotted
along 15 years. Statistical significance between the two groups is shown as log-rank test, P-valueo0.007. (d) TRAIL-induced cell death in breast and prostate human cancer
cell lines was evaluated by CellTiter-Glo luminescence assay and levels of PLAU mRNA were extracted from Affymetrix GeneChip U133 Plus 2.0 array-based transcript
profiling (see Materials and Methods). Correlation plot between cell death upon TRAIL treatment and PLAU mRNA levels is displayed (Pearson’s correlation r¼ 0.82,
two-tailed P-valueo0.003). The average of three technical replicates representative of three independent biological experiments is shown. (e) Correlation between PLAU
mRNA expression and the apoptotic response to TRAIL of a publically available data set of breast cancer cell lines.37 Twenty breast cancer cell lines were grouped according
to whether they were reported to display an apoptotic rate higher (‘High’) or lower (‘Low’) than 50% upon TRAIL treatment.37 PLAU mRNA levels in each group were calculated
from the transcriptome data set and are displayed as box plots of the median and interquartile range (25–75%). *P-valueo0.05. Cell lines classified as showing ‘Low’ and
‘High’ apoptotic rate upon TRAIL and the corresponding PLAU mRNA levels in arbitrary units (‘AU’) are specified on the right
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Figure 3 uPA expression is required for cell survival upon TRAIL treatment in RAS-derived stepwise tumorigenic cells. (a) Effect of uPA depletion on the response of
BJELR cells to TRAIL. Cells were transfected with pooled siRNAs targeting PLAU mRNA (‘siPLAU’), Death Receptor 5 mRNA (‘siDR5’), cFlip mRNA (‘siFlip’) or non-targeting
scramble siRNAs (‘scr’). Forty-eight hours after transfection, cells were either left untreated as control of basal cell death or challenged with 1mg/ml TRAIL during 16 h. Flow
cytometry analysis was performed to assess the percentage of cells displaying sub-G1 DNA. Results from at least two independent biological replicates are displayed as
histograms (mean±S.D.). (b) Time course analyzing the effect of uPA or uPAR depletion on the apoptotic response of BJELR cells to TRAIL. Cells were transfected with
pooled siRNAs targeting PLAU mRNA (‘siPLAU’), PLAUR mRNA (‘siPLAUR’) or non-targeting scramble siRNAs (‘scr’). Forty-eight hours after transfection, cells were either
left untreated or challenged with 1mg/ml TRAIL. Apoptosis was determined by flow cytometry as the percentage of cells displaying positive labeling for cleaved PARP at 1, 3
and 7 h after treatment. Results from two independent biological replicates are displayed as histograms (mean±S.D.) and are representative of at least three independent
experiments. Statistical significance between either knock down relative to scramble-transfected cells was calculated. (c) Effect of uPA depletion on the sensitivity threshold of
BJELR cells to trigger TRAIL-induced apoptosis. BJELR cells were transfected with pooled siRNAs targeting PLAU mRNA (‘siPLAU’) or non-targeting scramble siRNAs (‘scr’).
Forty-eight hours after transfection, cells were either left untreated (white bars) or treated with increasing doses of TRAIL (30, 60, 125, 250 or 500 ng/ml TRAIL, black bars)
during 3 h. Apoptosis was analyzed by flow cytometry as the percentage of cells displaying positive labeling for cleaved PARP. Results obtained from two independent
biological replicates are displayed as histograms (mean±S.D.). Statistical significance between uPA knockdown relative to scramble-transfected cells at the corresponding
dose of TRAIL was calculated. (d) Caspase dependency of TRAIL-induced cell death in uPA knockdown cells. BJELR cells were transfected either with pooled siRNAs
targeting PLAU mRNA (‘siPLAU’) or non-targeting scramble siRNAs (‘scramble’), and 48 h after transfection, cells were either pretreated with 100mM zVAD.fmk caspase
inhibitor or vehicle (dimethylsulfoxide (DMSO)) for 1 h and were either left unchallenged or treated with 1 mg/ml of TRAIL for 5 h. Apoptosis was analyzed by flow cytometry as
the percentage of cells displaying positive labeling for cleaved PARP. Results obtained from two independent biological replicates are displayed as histograms (mean±S.D.).
(e) Generation of cleaved products of caspase-3, caspase-9 and PARP at early time points of the response to TRAIL. BJELR cells were transfected either with pooled siRNAs
targeting PLAU mRNA (‘siPLAU pool’), four individual siRNAs targeting different regions of the PLAU mRNA (‘no. 7, no. 8, no. 9 and no. 10’, see Supplementary Figure S4b) or
non-targeting scramble siRNAs (‘scr’). Forty-eight hours after transfection, cells were left untreated (‘ ’) or challenged with 1 mg/ml TRAIL (‘þ ’) during 45 min and total cell
extracts were processed for western blot. Caspase-3 (‘Casp-3’), caspase-9 (‘Casp-9’) and PARP cleavage were analyzed. b-Actin, loading control. (f) Cellular levels of pro- and
antiapoptotic proteins reported to modulate TRAIL-induced apoptosis upon uPA knockdown. BJELR cells were transfected either with pooled siRNAs targeting PLAU mRNA
(‘siPLAU’) or non-targeting siRNAs (‘scr’), and 48 h after transfection, total cell extracts were processed for western blot analyzing the indicated pro- and antiapoptotic proteins. uPA
level in control samples and upon knock down is shown. a-Tubulin, loading control. (g) Requirement of the intrinsic mitochondrial pathway for triggering TRAIL-induced apoptosis in
uPA-depleted cells (top panel). Cells were transfected with pooled siRNAs targeting PLAU mRNA (‘siPLAU’), Bak mRNA (‘siBak’), Bim mRNA (‘siBim’), Bid mRNA (‘siBid’), non-
targeting scramble siRNAs (‘scr’) or double-transfected (‘siPLAUþ siBak’, ‘siPLAUþ siBim’ and ‘siPLAUþ siBid’). Forty-eight hours after transfection, cells were either left
untreated or challenged with 1mg/ml TRAIL during 7 h. Apoptosis was determined by flow cytometry as the percentage of cells displaying positive labeling for cleaved PARP. Results
obtained from two biological replicates are displayed as histograms (mean±S.D.) and are representative of a least three independent experiments. Statistical significance in (a, b, c
and g) was calculated by applying two-tailed, unpaired Student’s t-test, ***P-valueo0.005; **P-valueo0.005; *P-valueo0.05
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(Figure 3b) or to increasing doses of the cytokine (Figure 3c),
and the percentage of apoptotic cells was analyzed. uPA
depletion resulted in a B4-fold increase of sensitivity for
triggering cell death upon TRAIL challenge, supporting the
notion that diminishing uPA levels reduces the cellular threshold
for triggering TRAIL-induced cell death (Figures 3b and c).
Although it is widely accepted that apoptosis is the main
type of cell death triggered through DRs of the TNF family,
it was reported that TNF and TRAIL could trigger caspase-
independent necroptosis.44 To elucidate the molecular
mechanisms underlying sensitization to TRAIL upon uPA
knockdown, its dependence on caspase activity was analyzed.
We observed that TRAIL-induced cell death was abolished in
uPA knockdown and control samples in the presence of the
pancaspase inhibitor zVAD.fmk (Figure 3d). Moreover,
western blot assays revealed that uPA depletion promoted
the generation of cleaved products of caspases-3, caspase-9
and PARP at earlier time points of exposure to TRAIL as
compared with controls (Figure 3e and Supplementary
Figure 4a). These results were obtained by using an siRNA
pool as well as four individual siRNAs targeting different
regions of PLAU mRNA (Figure 3e and Supplementary
Figure 4b), supporting that the increase in apoptosis was
neither due to a synthetic nor to an individual off-target effect
of these siRNA molecules. Taken together, our results
demonstrate that the increased cell death observed upon
uPA knockdown proceeds through the classical caspase-
dependent TRAIL-induced apoptosis cascade.
Enhanced sensitivity to TRAIL-induced apoptosis upon
uPA knockdown could originate from an imbalance of pro-
and/or antiapoptotic proteins regulating the response to
TRAIL. Indeed, alterations in levels of Bcl-2 family members
have been previously reported upon uPAR knockdown in
cancer cells.38,45 In that regard, increased levels of proapop-
totic Bim and Bak were observed, indicating that uPA
knockdown changes the expression pattern of Bcl-2 family
members to a proapoptotic setting (Figure 3f). Therefore, we
investigated whether a cross-talk between the extrinsic and
intrinsic apoptotic pathways was required for the sensitization
effect observed upon uPA knockdown. By concomitantly
decreasing the levels of either Bak, Bim, Bid and of PLAU, we
showed that the enhanced sensitivity to TRAIL-induced
apoptosis upon uPA depletion was significantly diminished
by reducing Bim, whereas a decrease of Bak levels did not
have any significant effect (Figure 3g and Supplementary
Figure 4c). Moreover, Bid-mediated activation of the intrinsic
mitochondrial apoptotic cascade had only a mild effect on the
sensitization observed upon uPA depletion, suggesting that
other molecular mechanisms besides the activation of the
intrinsic mitochondrial cascade underlie the sensitization to
TRAIL in uPA-depleted cells. Previous reports described the
involvement of MAPK, Akt and NF-kB signaling in cell survival
upon TRAIL challenge.17 In this context, we observed that
populations of BJELR cells surviving TRAIL treatment display
increased levels of ERK1/2, Akt and IkBa phosphorylation as
compared with those in the initial naive cell population
(Figure 4a). Among these cascades, ERK1/2 and Akt were
described as modulated by the uPA/uPAR system.39,46,47
Therefore, abnormal ERK1/2 and/or Akt phosphorylation
could account for the enhanced apoptotic response to TRAIL
in uPA-depleted cells. To substantiate this hypothesis, total
and phosphorylated ERK1/2 and Akt were analyzed upon uPA
knockdown and, whereas no differences in Akt phosphoryla-
tion were found, basal ERK1/2 phosphorylation decreased in
the whole cell population (Figures 4b and c). Importantly,
blocking ERK1/2 phosphorylation in BJELR cells by using
U0126 MEK1/2 inhibitor (Supplementary Figure 4d)
enhanced their apoptotic response to TRAIL (Figure 4d).
These data suggest that the ERK1/2 cascade supports cell
survival upon exposure to TRAIL in this model; thus,
decreased basal ERK1/2 signaling as a consequence of
uPA depletion accounts – at least partially – for the enhanced
sensitivity to TRAIL-induced cell death.
uPA depletion alters DcR2 recruitment to the
DISC-promoting caspase-8 processing. uPA knockdown
resulted in a higher number of cells displaying caspase-8
cleavage upon TRAIL treatment (Figure 5a), suggesting that
levels of DISC components and/or DISC composition itself
could be affected upon uPA depletion. In that regard,
no changes in total protein levels of DR4, DR5, DcR1, cFlip,
FADD or procaspase-8 were observed, whereas a mild
decrease on total DcR2 was evidenced (Figure 5b, lane 1
versus 3 and Supplementary Figure 5a). However,
no differences were detected when surface levels of DR4,
DR5, DcR1 and DcR2 were analyzed by flow cytometry
(Figure 5c). Therefore, we analyzed whether increased
caspase-8 activation originated from changes of the DISC
composition. For that, the DISC was immunoprecipitated by
using anti-DR5 antibodies and the co-immunoprecipitation of
cognate DISC members was revealed by western blot.
We observed that DcR2 displayed preligand association to
DR548 (Figure 5b, lane 5), which was further enhanced by
exposure to the cytokine (Figure 5b, lane 6 versus 5),
whereas DcR1 was not detected at the DISC (not shown).
Moreover, recruitment of FADD, DR4 as well as recruitment
and cleavage of procaspase-8 and cFlipL (but not FlipS)
were entirely TRAIL-dependent (Figure 5b, lane 6 versus 5).
Interestingly, uPA knockdown resulted in lower preligand
association of DcR2 with DR5 (Figure 5b, lane 7 versus 5)
and in a reduced recruitment of DcR2 to the DISC
after TRAIL exposure (Figure 5b, lane 8 versus 6). The
antiapoptotic role of DcR2 in stepwise models was confirmed
by DcR2 knockdown followed by TRAIL challenge (Figures
5d and e and Supplementary Figures 5b and c). Interestingly,
neither uPA nor uPAR co-immunoprecipitated with DR5,
suggesting that these molecules are not components of the
DISC in our experimental conditions. Concomitant to the
decrease of DcR2 recruitment upon uPA knockdown,
enhanced FADD and caspase-8 recruitment and cleavage
were observed (Figure 5b, lane 8 versus 6). Taken together,
these results show that increased apoptotic response to
TRAIL in uPA-depleted cells arises – in part – from the
reduced interaction of the antiapoptotic DcR2 with DISC
components.
Discussion
Despite the conceptually attractive therapeutic features
of the TRAIL signaling pathway – such as its unique tumor
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selectivity – only few cases of stable disease and partial
remission were observed in clinical trials, suggesting that
human tumors are largely resistant to TRAIL-based mono-
therapies.49 These disappointing results were rather unex-
pected, given the well-documented tumoricidal effects of
TRAIL in vitro and the cancer-protective activities of the
TRAIL cascade in mouse knockout studies. Indeed, the
TRAIL pathway is a natural component of the tumor-
surveillance system in mammals that was shown to modulate
tumor onset/progression and to participate in T-cell-mediated
immune defense against tumors in allogenic graft-versus-
tumor settings.16 Facing TRAIL challenge, cancer cells may
need to develop strategies to survive and proliferate in vivo by
acquiring resistance to this cytokine at early steps of the
neoplastic transformation. Indeed, activation of survival
cascades supporting evasion from apoptosis is one of the
hallmarks of cancer.27 In that regard, acquisition of resistance
to TRAIL-induced cell death during neoplastic transformation
may be based on two general mechanistic principles:23 (i) key
components of the TRAIL pathway may be silenced (e.g.,
epigenetically) and/or mutated, resulting in a non- or
subfunctional signaling cascade and (ii) cancer cells may
hijack a functional TRAIL-apoptotic pathway in vivo through
the activation of survival cascades that counterbalance
TRAIL-induced cell death. In such a scenario, cancer cells
would ‘hit two birds with one stone’ by simultaneously evading
from the apoptotic TRAIL challenge imposed by immune
surveillance and gaining survival advantage through shifting
the TRAIL response from apoptosis to survival/migration. It is
therefore of major importance to identify tumor-related
features of those cancer cells that have maintained a
functional TRAIL-apoptotic pathway and to assess the relative
impact of the associated apoptogenic and survival/prolifera-
tive functions of this cascade. By following such an approach,
we identified PLAU mRNA as a molecule whose high
expression is characteristic of cancer cells with a functional
TRAIL-apoptotic cascade and whose level has a direct
correlation with the sensitivity of cancer cells to trigger
TRAIL-induced apoptosis. Surprisingly, we faced an apparent
conundrum, as depletion of uPA in these apoptosis-respon-
sive cells enhanced cell death upon cytokine challenge. In that
regard, we observed that TRAIL-sensitive cells expressing
high levels of PLAU mRNA triggered fractional killing upon
TRAIL challenge and survivor cells displayed increased
prosurvival signaling. Thus, that uPA and uPAR depletion
Figure 4 uPA knockdown affects ERK1/2 survival signaling. (a) Phosphoryla-
tion levels of ERK1/2, Akt and regulators of NF-kB signaling (IkBa) in transformed
cells surviving TRAIL treatment. BJELR cells were either left untreated (‘control’) or
treated with TRAIL (1 mg/ml) during 7 or 16 h. Apoptotic cells (‘apop’) were collected
by successive washes and non-apoptotic attached cells (‘surv’) were harvested for
western blot analysis. Total and phosphorylated levels of ERK1/2 (Thr202/Tyr204),
Akt (Ser 473) and IkBa (Ser32/36) were analyzed. Caspase-8 cleavage (‘Casp-8’)
was evaluated in each cell population. a-Tubulin, loading control. (b) Phosphoryla-
tion status of ERK1/2 and Akt upon uPA knockdown. BJELR cells were left non-
transfected (‘mock’) or transfected either with pooled siRNAs targeting PLAU mRNA
(‘siPLAU’) or non-targeting scramble siRNAs (‘scr’). Forty-eight hours after
transfection, total and phosphorylated protein levels of ERK1/2 (Thr202/Tyr204)
and Akt (Ser 473) were analyzed by western blot analysis. a–Tubulin, loading
control. (c) Distribution of total (ERK1/2 Alexa488) and phosphorylated ERK1/2
(pERK1/2-Alexa 488; Thr202/Tyr204) in populations of BJELR cells untreated
(‘mock’), scramble transfected (‘scr’) and uPA depleted (‘siPLAU’) was analyzed by
flow cytometry. Images represent the distribution of fluorescence within each
sample for a representative experiment out of three independent replicates. Isotypic
IgG1 (‘IgG1’) was used as control for background florescence. (d) Requirement of
ERK1/2 signaling for cell survival upon TRAIL challenge. BJELR cells were either
treated for 1 h with 20mM U0126 MEK1/2 inhibitor or vehicle (DMSO). Apoptosis in
untreated samples (‘U0126’, ‘DMSO’) and upon 3 h of treatment with 1mg/ml of
TRAIL (‘U0126þ TRAIL’, ‘DMSOþ TRAIL’) was analyzed by flow cytometry as the
percentage of cells with positive labeling for cleaved PARP. Images correspond to
one representative experiment out of four independent replicates. Percentage of
cleaved PARP-positive cells is indicated in the upper right quadrant
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resulted in diminished survival upon challenge with TRAIL
highlighted a functional involvement of this cascade in evasion
from TRAIL-induced apoptosis. Particularly, we demonstrate
that uPA knockdown shifts the profile of Bcl-2 family members
to proapoptotic, decreases basal prosurvival ERK1/2 signal-
ing and results in abnormal recruitment of DcR2 to the DISC.
The regulation of ERK1/2 phosphorylation by the uPA/uPAR
system can involve the interaction between uPAR and
integrins, uPAR and epidermal growth factor (EGF) receptor,
as well as cell signaling triggered by soluble uPAR.50 In these
scenarios, uPAR has a central role in modulating the ERK1/2
cascade. In our experiments, sensitization to TRAIL-induced
cell death was also observed upon uPAR knockdown, but
surprisingly, no major differences in ERK1/2 phosphorylation
were seen (data not shown). This suggests the existence of a
uPAR-independent/uPA-dependent modulation of ERK1/2
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signaling in this experimental model. Supporting this hypo-
thesis, uPAR-independent uPA signaling has been ascribed
its binding to other receptors (e.g., aMb2-, a5b5-integrin) and/
or to its uPAR-independent proteolytic activity.51,52
That depletion of uPA alters the DISC composition by
reducing the recruitment of antiapoptotic DcR2 suggests a
cross-talk between uPA signaling and the formation of TRAIL
receptor complexes. Importantly, regulation of signaling from
plasma membrane-bound receptors by uPA/uPAR has been
reported. Indeed, it has been shown that binding of uPAR to
integrins, FPRL1 and EGF receptors subverts the ligand-
dependent signaling toward the formation of new signaling
complexes.50 Interestingly, neither uPAR nor uPA were found
to interact with the DISC in our experimental conditions,
suggesting that the modulation of DISC composition/proces-
sing in response to TRAIL does not rely on a direct interaction
between these molecules and TRAIL receptors.
Finally, several factors have been described to correlate
with sensitivity or resistance to TRAIL-induced cell death in
tumor cells. For example, the expression of GALNT14
correlates with sensitivity to TRAIL-induced apoptosis in
human cancer cell lines and its predictive value is currently
tested in phase II clinical trials.53 Expression of the
homeoprotein Six1 was shown to correlate with resistance
to TRAIL-induced cell death and its depletion sensitized
cancer cells to apoptosis by this cytokine.54 In this context,
we show that high PLAU mRNA levels correlate with TRAIL
responsiveness and demonstrate that depletion of uPA
promotes the apoptogenic action of TRAIL decreasing the
risk of generating resistant cells that may turn TRAIL signaling
from apoptosis to proliferation/survival. Therefore, uPA/uPAR
adds another facet to the TRAIL signaling, which may be
considered in therapeutic settings, also in view that TRAIL-
apoptotic action is independent of p53.1 In that regard, we
have shown that high levels of PLAU mRNA are observed in
breast tumors showing Her2þ , PgR and/or p53 mutant
phenotypes and that such levels correlate with the apoptotic
response of breast cancer cells to TRAIL, suggesting that this
type of cancer may express a functional TRAIL cascade.
Importantly, first-in-man studies modulating uPA activity55
and testing TRAIL-based therapeutics1,49 are ongoing. Thus,
combinatorial therapies may be envisaged for patients
bearing tumors with high PLAU expression and p53
mutations, which are expected to have a poor response to
standard treatments.34–36
Materials and Methods
Antibodies. Antibodies for western blotting recognizing the indicated proteins
were purchased from Cell Signaling (Beverly, MA, USA; caspase-8 1C12 no. 9746,
cleaved caspase-3 D175 no. 9661, caspase-9 no. 9502 and PARP no. 9542, DR5 no.
3696, DcR2 no. 8049, DcR1 no. 4756, BID no. 2002, Bcl-2 no. 2872, Bcl-xl no. 2762,
PTEN no. 9552, PUMA no. 4976, Bak no. 6947, Bim no. 2933, Bax no. 5023,
Bad no. 9239, Mcl1 no. 4572, XIAP no. 2045, survivin no. 2808, IAP1 no. 4952, IAP2
no. 3130, ERK1/2 no. 9102, pERK1/2 no. 9101, Akt no. 9272, pAkt no. 9271, IkBa
no. 4814, pIkBa no. 9246), Santa Cruz Biotechnology (Santa Cruz, CA, USA; b-actin
clone sc-1615, a-tubulin sc-32293, uPA sc-14019), Millipore EMD Millipore
Corporation (Billerica, MA, USA; DR4 AB16955), Alexis Biochemicals, Enzo Life
Sciences (Farmingdale, NY, USA), (cFlip ALX-804-428-c050), BD Transduction
Laboratories (San Jose, CA, USA; FADD 610399) and Abcam (Cambridge, UK; uPAR
ab3129). For flow cytometry assays, APO2.7-PE was purchased from Beckman
Coulter (Fullerton, CA, USA; IM2088U), cleaved PARP (no. 8978; no. 6987) and
cleaved caspase-8 (no. 9496) from Cell Signaling. DISC immunoprecipitation assays
used anti-DR5 (AF631) purchased from R&D Systems (Minneapolis, MN, USA).
Cell Lines. Cells from stepwise tumorigenesis systems were cultured in DMEM
(1 g/l glucose)þMed 199 (4 : 1)þ 10% FCS heat-inactivated (BJ-derived model)
and DMEM (1 g/l glucose)þ 10% FCS heat-inactivated (HEK-derived model).
Culture medium was supplemented with 400mg/ml hygromycin (hTERT selection),
400mg/ml G418 (SV40 ER selection) and 1mg/ml puromycin (H-rasV12 selection)
when required. Expression of SV40 ER and H-rasV12 was confirmed by western
blot. LNCaP, PC-3, DU-145, MDA-231, MCF-7, BT-474, 22Rv1 and SKBR3 were
obtained from American Type Culture Collection (ATCC, Manassas, VA, USA),
and JIMT-1 was purchased from Deutsche Sammlung von Mikroorganismen und
Zellkultutren (DSMZ, GmbH, Germany) and grown in recommended media. LAPC-
4 cells (a kind gift from Prof. C Sawyer, Los Angeles, CA, USA) were grown in
Iscove’s medium supplemented with 7.5% FBS supplemented with 2 mM
L-glutamine, 1% penicillin/streptomycin and 10 nM R1881. VCaP and PC-3MPro4
cells were received from Adrie van Bokhoven (University Medical Center
Nijmegen, Nijmegen, The Netherlands) and Marco Ceccini (University of Bern,
Bern, Switzerland), respectively, and cultured in RPMI-1640 supplemented with
10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin.
Microarrays analysis for stepwise tumorigenesis models.
Illumina arrays were normalized by quantiles method in R using lummi package.56
Analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon
and BRB-ArrayTools Development Team. Briefly, univariate t-tests were
performed for the different class comparisons (BJ versus BJELR, BJEL versus
BJELR, HEK versus HA1ER, HA1E versus HA1ER). The differential expressed
genes with a P–value o0.01, false discovery rate o0.01 and fold change (FC)
42.5 were selected. Multiple probe i.d.’s were discarded and gene list containing
unique names was composed. Hierarchical clustering (complete linkage) and
heatmaps were performed using Cluster 3.0 (http://bonsai.hgc.jp/Bmdehoon/
software/cluster/software.htm) and Java TreeView,57 respectively.
In silico analysis of PLAUmRNA expression. In silico data mining for
gene expression levels of PLAU mRNA in clinical samples was carried out using
the in silico transcriptomics database (IST) developed at VTT Technical Research
Center in Finland. The database covers 113 million data points and is available
from the GeneSapiens website (http://www.genesapiens.org).58
Figure 5 Altered recruitment of inhibitory components to the DISC promotes caspase-8 activation in uPA knockdown cells. (a) Time-course analysis of procaspase-8
cleavage. BJELR cells were transfected either with pooled siRNAs targeting PLAU mRNA (‘siPLAU’) or non-targeting scramble siRNAs (‘scramble’). Forty-eight hours after
transfection, cell populations were either left untreated or challenged with 1mg/ml TRAIL during 1, 3 or 7 h and the percentage of cells displaying cleaved caspase-8 (‘C8’) was
determined by flow cytometry. Images from one representative experiment out of three independent replicates are shown. Percentage of cleaved C8-positive cells is indicated.
(b) DISC composition in uPA-depleted cells. BJELR cells were transfected either with pooled siRNAs targeting PLAU mRNA (‘siPLAU’) or non-targeting scramble siRNAs
(‘scr’), and 48 h after transfection, cell populations were either left untreated or challenged with TRAIL (1 mg/ml) during 30 min. Immunoprecipitation of Death Receptor 5
(IP-DR5) was performed and co-immunoprecipitation of cognate DISC components, uPA and uPAR, was analyzed by western blot analysis. Immunoprecipitation using
isotypic IgG1 (‘IgG1’) was used as background control. (c) Surface levels of TRAIL-Rs upon uPA knockdown. BJELR cells transfected either with pooled siRNAs targeting
PLAU mRNA (‘siPLAU’) or non-targeting scramble siRNAs (‘scr’). Forty-eight hours after transfection, surface levels of Death Receptor 5 (‘DR5’), Death Receptor 4 (‘DR4’),
Decoy Receptor 1 (‘DcR1’) and Decoy Receptor 2 (‘DcR2’) were analyzed by flow cytometry. Isotypic IgG1 labeling was used as control for background fluorescence in
scramble- (‘IgG1 scr’) and siPLAU- (‘IgG1 siPLAU’) transfected cells. (d) Antiapoptotic role of DcR2. BJELR cells were transfected either with pooled siRNA targeting Death
Receptor 5 mRNA (‘siDR5’), Decoy Receptor 2 mRNA (‘siDcR2’) or non-targeting scramble siRNAs (‘scr’), and 48 h after transfection, cell populations were either left
untreated or challenged with TRAIL (1mg/ml) during 3 h. Apoptosis was determined as the percentage of cells with positive labeling for cleaved PARP by flow cytometry.
Histograms represent the mean±S.D. of three independent biological replicates. Statistical significance was calculated by applying two-tailed, unpaired Student’s t-test,
*P-valueo0.05; **P-valueo0.005. (e) Efficiency of DR5 and DcR2 knockdown at 48 h after transfection analyzed by western blot analysis. a-Tubulin, loading control
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To determine the expression of PLAU mRNA in 14 different cancer cell lines, we
utilized the profiling data from the following resources, which have all been
generated using Affymetrix GeneChip U133 Plus 2.0 arrays: (1) GlaxoSmithKline
from the National Cancer Institute’s cancer Bioinformatics Grid (caBIG). This data
set included genome profiling data for over 300 cancer cell lines, available through
the caArray open source microarray data management system (https://
cabig.nci.nih.gov/tools/caArray). (2) VTT in-house cell line gene expression profiling
database58 included data from four breast cancer (JIMT-1, SKBR3, MCF7, BT474)
and six prostate cancer (DU-145, PC3, VCAP, LNCaP, LAPC-4 and 22RV1) cell
lines. (3) Gene Expression Omnibus (GEO) database. Breast cancer expression set
includes breast normal and breast cancer samples from 483 records with GEO
series i.d.’s GSE6532, GSE9195, GSE12276, GSE12276 and GSE19615. Only
samples with survival information attached were used from the series. From these
samples, 79 are annotated as Her2( ) and 36 as Her2(þ ). Probes were
summarized according to improved probe definitions (custom CDF hgu133plus2h-
sensgcdf, version 12)59 and data were normalized using the robust multiarray
(RMA) average expression measure with R/Bioconductor v.2.9.1. Kaplan–Meier
plots were drawn using R standard functions. P-values for survival were calculated
with w2 statistics of the rank sum. For between-group comparisons at the gene level
two-tailed Student’s t-test was used.
Transfection. Smart pool siRNAs targeting DR5 mRNA (L-004448-00), DR4
mRNA (L-008090-00), DcR2 mRNA (L-008092-01), cFLIP mRNA (L-003772-00),
PLAU mRNA (L-006000-00), PLAUR mRNA (L-0063388-00), Bid mRNA
(L-004387-00-0005), Bak (J-003305-07) and non-targeting scrambled no. 1
(D-001810-10-05), as well as single siRNAs targeting different regions of PLAU
mRNA (LU-006000-00) were purchased from Dharmacon, Thermo Scientific
(Waltham, MA, USA). siRNA targeting Bim (no. 6518) was purchased from Cell
Signaling. These siRNAs were transfected into BJELR and/or HA1ER cells by
using RNAi Max Lipofectamine following the vendor’s intructions (Invitrogen, Life
Technologies, Carlsbad, CA, USA). Twenty-four hours after transfection, the
culture medium was replaced and cells were incubated under normal growth
conditions (37 1C, 5% CO2) for additional 24 h.
Apoptosis measurement. Apoptosis was determined either as the
percentage of cells displaying sub-G1 DNA content or a positive immunostaining
for the APO 2.7 mitochondrial marker, cleaved PARP or cleaved caspase-8
following the manufacturer’s instructions. Apoptotic rate in non-treated control cells
and upon TRAIL challenge is displayed as the percentage of cells presenting a
positive staining for the indicated marker. When displayed as histograms, each
data set was derived from at least two independent biological replicates.
Analysis of growth inhibition upon TRAIL. Cell viability following
exposure to TRAIL in 11 different cancer cell lines (LNCaP, PC-3, DU-145, MDA-231,
MCF-7, BT-474, 22Rv1, SKBR3, VCap and LAPC) was determined by CellTiter-Glo
Luminescence Assay following the manufacturer’s instructions (Promega, Madison,
WI, USA). Briefly, cells were plated in 384-well plates, and 24 h after plating, cells
were treated with 400 ng/ml of TRAIL for 48 h and cell viability was measured. The
percentage of cell viability was determined as: luminescence value in TRAIL-treated
cells/luminescence value in non-treated controls. Percentage of cell death displayed
in Figure 2d was calculated as: 100%% of cell viability.
Growth curve assays. HA1ER and BJELR cells were plated in 48-well plates,
and after 20 h, a first dose of TRAIL (100 or 400 ng/ml) was added to the medium.
A second, a third and a fourth dose were administered 16, 40 and 64 h after the first
treatment. Growth curves were obtained using Incucyte (Essen Instruments, Ann
Arbor, MI, USA) under normal culture conditions. Phase-contrast images of cells were
taken every hour during 4 days and temporal plots of confluence were established to
analyze cell growth. Results are shown as the mean of two technical replicates and
are representative of three independent biological repeats.
Western blot assays. Samples were harvested in RIPA buffer, separated by
SDS-PAGE and electrotransferred onto nitrocellulose membranes. Membranes were
blocked with 5% non-fat dry milk and 0.1% Tween-20 in PBS for 1 h at room
temperature and incubated overnight at 4 1C with primary antibodies according to the
manufacturer’s instructions, followed by incubation with corresponding secondary
peroxidase-conjugated antibodies. b-Actin or a-tubulin was used as an internal
standard for protein loading. Immunoreactive bands were visualized by enhanced
chemiluminescence and subsequent exposure to hyperfilm (Amersham, GE
Healthcare, Amersham, UK). Images were scanned and processed by Adobe
Photoshop CS2 software (San Jose, CA, USA). Images from one representative
experiment out of at least two biological replicates are displayed.
Surface levels of TRAIL receptors. Antibodies were purchased from
Diaclone Immunology Products (Diaclone, Besancon, France; TRAIL R1 854.852.010;
TRAIL R2 854.862.010; TRAIL R3 854.892.010 and TRAIL R4 854.972.010) and
detection was performed following the manufacturer’s instructions.60
DISC immunoprecipitation. BJELR cells were plated in a confluency of
106 cells per 10 cm Petri dishes. Twenty-four hours later, cells were exposed to
TRAIL 1 mg/ml) during 30 min at regular growing conditions (37 1C; 5% CO2). Cells
were washed with ice-cold PBS and lysed in 1 ml of lysis buffer (30 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 5 mM KCl, 10% glycerol, 2 mM EDTA (pH 8.0)) freshly
supplemented with complete, EDTA-free protease inhibitor cocktail (Roche,
Mannheim Germany; no. 11873580001), phosphatase inhibitors (PhosStop;
Roche) and 1% Triton X-100 (Bio-Rad). Lysates were precleared with Pure
Proteome Protein G magnetic beads (Millipore; LSKMAGG02) and the DISC was
immunoprecipitated by using 10mg of anti-DR5 antibody bound to Pure Proteome
Protein G magnetic beads (Millipore; LSKMAGG02). Immunoprecipitates were
processed for immunoblotting as described in western blot section.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. Stepwise tumorigenesis systems were kindly provided by
William C Hahn (Dana-Farber Cancer Institute). Transcriptome analyses were
performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB-
ArrayTools Development Team. We thank the European Commission (LSHC-CT-
2005-518417 ‘Epitron’, HEALTH-F4-2007-200767 ‘Apo-Sys’H Gronemeyer and
O Kallioniemi laboratories), the Ligue Contre le Cancer (H Gronemeyer, equipe
labellise´e), the Association pour la recherche sur le cancer (ARC), the Agence
Nationale de la Recherche (ANR) and the Institut National du Cancer (INCa) for
financial support. We thank Irene Yujnovsky and Maximiliano Portal for helpful
discussions and critical reading of the manuscript and Dorothe´e Jean for technical
assistance. Yelyzaveta Shlyakhtina is a recipient of a Doctoral Fellowship from the
IGBMC International PhD Program, Danilo G Ceschin was a recipient of a Postdoctoral
fellowship from Foundation pour la Recherche Medicale and Valeria Pavet was a
recipient of a Senior Postdoctoral fellowship from the Ligue Contre le Cancer.
1. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the
potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621–3630.
2. Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the
cytotoxic ligand TRAIL. Science 1997; 276: 111–113.
3. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a
new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr
Biol 1997; 7: 693–696.
4. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al.
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386–5397.
5. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES.
Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.
J Biol Chem 1997; 272: 25417–25420.
6. Oberst A, Pop C, Tremblay AG, Blais V, Denault JB, Salvesen GS et al. Inducible
dimerization and inducible cleavage reveal a requirement for both processes in caspase-8
activation. J Biol Chem 2010; 285: 16632–16642.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of
apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem 1996; 271: 12687–12690.
8. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer
Gene Ther 2005; 12: 228–237.
9. Lalaoui N, Morle A, Merino D, Jacquemin G, Iessi E, Morizot A et al. TRAIL-R4 promotes
tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.
PLoS One 2011; 6: e19679.
10. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al.Control of TRAIL-
induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–821.
11. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death
domain-containing receptor for TRAIL. Science 1997; 277: 815–818.
12. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M et al. FLIP prevents
apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic
drugs, and gamma irradiation. J Immunol 1998; 161: 3936–3942.
PLAU is a marker and modulator of TRAIL signaling
V Pavet et al
10
Cell Death and Disease
13. Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain-containing
protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci USA 1997;
94: 10717–10722.
14. Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D. CASH,
a novel caspase homologue with death effector domains. J Biol Chem 1997; 272:
19641–19644.
15. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2
overexpression. Oncogene 2002; 21: 2283–2294.
16. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset,
progression and therapy. Nat Rev Cancer 2008; 8: 782–798.
17. Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA. Non-canonical kinase signaling
by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death
Differ 2013; 20: 858–868.
18. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival
and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by
NF-kappaB. Oncogene 2003; 22: 3842–3852.
19. Flusberg DA, Roux J, Spencer SL, Sorger PK. Cells surviving fractional killing by TRAIL
exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell
2013; 24: 2186–2200.
20. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel
receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis,
yet retains an incomplete death domain. Immunity 1997; 7: 813–820.
21. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell
variability in TRAIL-induced apoptosis. Nature 2009; 459: 428–432.
22. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular
determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related
apoptosis-inducing ligand. J Biol Chem 2005; 280: 40599–40608.
23. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL
to successful cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene 2012; 32: 1341–1350.
24. Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance
mechanisms can be overcome by proteasome inhibition but not generally by synergizing
agents. Cancer Res 2011; 71: 1883–1892.
25. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA.
Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464–468.
26. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL et al. Human
breast cancer cells generated by oncogenic transformation of primary mammary epithelial
cells. Genes Dev 2001; 15: 50–65.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:
646–674.
28. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP et al. Multivalent DR5
peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res
2010; 70: 1101–1110.
29. Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn WC et al.
Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by
DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther 2011; 10: 1611–1623.
30. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting
of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5: 501–512.
31. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells
to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Cancer Res 2004; 64: 3922–3927.
32. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O’Higgins NJ. Urokinase plasminogen
activator: a prognostic marker in breast cancer including patients with axillary node-
negative disease. Clin Chem 1998; 44(Part 1): 1177–1183.
33. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C et al.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its
inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116–128.
34. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M et al. Randomized
adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients
identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
J Natl Cancer Inst 2001; 93: 913–920.
35. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S et al. uPA and PAI-1 in
breast cancer: review of their clinical utility and current validation in the prospective
NNBC-3 trial. Adv Clin Chem 2008; 45: 31–45.
36. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F et al. Urokinase-type
plasminogen activator and its inhibitor type 1 predict disease outcome and therapy
response in primary breast cancer. Clin Breast Cancer 2004; 5: 348–352.
37. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS et al. TRAIL induces
apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast
Cancer Res Treat 2009; 113: 217–230.
38. Besch R, Berking C, Kammerbauer C, Degitz K. Inhibition of urokinase-type plasminogen
activator receptor induces apoptosis in melanoma cells by activation of p53. Cell Death
Differ 2007; 14: 818–829.
39. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA
activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol
2007; 31: 19–27.
40. Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous
downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering
apoptosis in breast cancer cells. Int J Oncol 2006; 28: 831–839.
41. Tkachuk N, Kiyan J, Tkachuk S, Kiyan R, Shushakova N, Haller H et al. Urokinase induces
survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic
stimulus. Biochem J 2008; 415: 265–273.
42. Cao DJ, Guo YL, Colman RW. Urokinase-type plasminogen activator receptor is involved
in mediating the apoptotic effect of cleaved high molecular weight kininogen in human
endothelial cells. Circ Res 2004; 94: 1227–1234.
43. Zhang X, Chaudhry A, Chintala SK. Inhibition of plasminogen activation protects against
ganglion cell loss in a mouse model of retinal damage. Mol Vis 2003; 9: 238–248.
44. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G,
Van Herreweghe F et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent
PARP-1 activation. Cell Death Differ 2012; 19: 2003–2014.
45. Krishnamoorthy B, Darnay B, Aggarwal B, Dinh DH, Kouraklis G, Olivero WC et al.
Glioma cells deficient in urokinase plaminogen activator receptor expression are
susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced
apoptosis. Clin Cancer Res 2001; 7: 4195–4201.
46. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its
receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is
required for increased cellular motility. J Biol Chem 1998; 273: 8502–8507.
47. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ et al.
Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated
kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires
focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is
associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol
Chem 2000; 275: 19382–19388.
48. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. Preligand
assembly domain-mediated ligand-independent association between TRAIL receptor 4
(TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102:
18099–18104.
49. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H. Towards novel paradigms for
cancer therapy. Oncogene 2010; 30: 1–20.
50. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2009;
11: 23–36.
51. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A et al. The urokinase plasminogen
activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005; 93:
205–211.
52. Konakova M, Hucho F, Schleuning WD. Downstream targets of urokinase-type
plasminogen-activator-mediated signal transduction. Eur J Biochem 1998; 253: 421–429.
53. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al.
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand
Apo2L/TRAIL. Nat Med 2007; 13: 1070–1077.
54. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A et al.
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis
and is associated with poor survival. Cancer Res 2007; 67: 3036–3042.
55. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, Muhlenweg B et al.
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers
uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011; 11: 617–634.
56. Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray.
Bioinformatics 2008; 24: 1547–1548.
57. Saldanha AJ. Java Treeview – extensible visualization of microarray data. Bioinformatics
2004; 20: 3246–3248.
58. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H et al. Systematic bioinformatic
analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types
of healthy and pathological tissues. Genome Biol 2008; 9: R139.
59. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. Evolving gene/transcript
definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;
33: e175.
60. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of
TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26:
7046–7055.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
PLAU is a marker and modulator of TRAIL signaling
V Pavet et al
11
Cell Death and Disease
